These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17317815)

  • 1. Prospect of targeting the CD40 pathway for cancer therapy.
    Vonderheide RH
    Clin Cancer Res; 2007 Feb; 13(4):1083-8. PubMed ID: 17317815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects for CD40-directed experimental therapy of human cancer.
    Tong AW; Stone MJ
    Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the CD40 pathway in the pathogenesis and treatment of cancer.
    Eliopoulos AG; Young LS
    Curr Opin Pharmacol; 2004 Aug; 4(4):360-7. PubMed ID: 15251129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology and clinical applications of CD40 in cancer treatment.
    Fonsatti E; Maio M; Altomonte M; Hersey P
    Semin Oncol; 2010 Oct; 37(5):517-23. PubMed ID: 21074067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40 and OX40 ligand are differentially regulated on asthmatic airway smooth muscle.
    Krimmer DI; Loseli M; Hughes JM; Oliver BG; Moir LM; Hunt NH; Black JL; Burgess JK
    Allergy; 2009 Jul; 64(7):1074-82. PubMed ID: 19220210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
    Vonderheide RH; Flaherty KT; Khalil M; Stumacher MS; Bajor DL; Hutnick NA; Sullivan P; Mahany JJ; Gallagher M; Kramer A; Green SJ; O'Dwyer PJ; Running KL; Huhn RD; Antonia SJ
    J Clin Oncol; 2007 Mar; 25(7):876-83. PubMed ID: 17327609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Janus faces of CD40 in cancer.
    Loskog AS; Eliopoulos AG
    Semin Immunol; 2009 Oct; 21(5):301-7. PubMed ID: 19647448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of agonistic anti-CD40 therapy in treatments for cancer.
    Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
    Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of microenvironmental CD40 signals on TRAIL- and drug-induced apoptosis in follicular lymphoma cells.
    Nuutinen U; Ropponen A; Eeva J; Eray M; Pellinen R; Wahlfors J; Pelkonen J
    Scand J Immunol; 2009 Dec; 70(6):565-73. PubMed ID: 19906199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40-induced countercurrent conduits for tumor escape or elimination?
    Murugaiyan G; Martin S; Saha B
    Trends Immunol; 2007 Nov; 28(11):467-73. PubMed ID: 17981086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo.
    Wu Y; Wang L; He X; Xu H; Zhou L; Zhao F; Zhang Y
    Cell Immunol; 2008; 253(1-2):102-9. PubMed ID: 18603231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.
    Vardouli L; Lindqvist C; Vlahou K; Loskog AS; Eliopoulos AG
    Cancer Gene Ther; 2009 Nov; 16(11):848-60. PubMed ID: 19461675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40 promotion of amyloid beta production occurs via the NF-kappaB pathway.
    Ait-Ghezala G; Volmar CH; Frieling J; Paris D; Tweed M; Bakshi P; Mullan M
    Eur J Neurosci; 2007 Mar; 25(6):1685-95. PubMed ID: 17432959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conundrum of CD40 function: host protection or disease promotion?
    Mathur RK; Awasthi A; Saha B
    Trends Parasitol; 2006 Mar; 22(3):117-22. PubMed ID: 16446115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
    Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
    Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling.
    Volmar CH; Ait-Ghezala G; Frieling J; Weeks OI; Mullan MJ
    Exp Cell Res; 2009 Aug; 315(13):2265-74. PubMed ID: 19422822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAF2 and p38 are involved in B cells CD40-mediated APE/Ref-1 nuclear translocation: a novel pathway in B cell activation.
    Merluzzi S; D'Orlando O; Leonardi A; Vitale G; Pucillo C
    Mol Immunol; 2008 Jan; 45(1):76-86. PubMed ID: 17599408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis.
    Suttles J; Stout RD
    Semin Immunol; 2009 Oct; 21(5):257-64. PubMed ID: 19540774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.